## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

- 1-41. Canceled.
- 42. (Currently amended) A compound of general formula I:

Ι

## wherein:

each  $R^1$  independently represents hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl, phenyl, heteroaryl or phenyl $C_{1-3}$  alkyl, where all phenyl and heteroaryl rings can be optionally substituted with one or more halogen,  $C_{1-4}$  alkyl or  $C_{1-4}$  alkoxy groups, or both substituents  $R^1$  may be taken together to form a saturated or partially unsaturated 5- or 6-membered ring, which can be optionally fused to a benzene ring;

A represents an imidazole, pyrazole, isoxazole or oxazole, an unsaturated or partially unsaturated 5- or 6-membered ring which can optionally contain from 1 to 3 heteroatoms selected from N, O and Sr where the substituents L and D are placed on adjacent atoms of ring A, and where additionally A can be optionally substituted with one or more substituents R2; L represents a single bond, -O-, -S- or -NR3-; B represents C1-6 alkyl or a ring selected from phenyl, heteroaryl and C3-7 cycloalkyl, where all said rings can be optionally substituted with one or more substituents R4; D represents phenyl or pyridine, each of which can be optionally substituted with one or more halogens: the groups A and -SO2NHP(O)(OR1), are placed on ring D in para position with respect to one another; each R2 independently represents halogen, cyano, nitro, carboxy,  $C_{1-4}$  alkyl,  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{1-4}$  haloalkyl, hydroxy,  $C_{1-4}$ hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, amino, C1-4 alkylamino, C1-4 dialkylamino, formyl, C1-4 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-4 haloalkoxycarbonyl, C1-4 alkoxyC1-3 alkyl, C1-4 alkylcarbonyloxy $C_{1-3}$  alkyl,  $C_{3-7}$  cycloalkyl $C_{1-4}$  alkoxy $C_{1-3}$  alkyl or  $C_{3-7}$  cycloalkoxy $C_{1-3}$  alkyl, or two substituents  $R^2$  on the same carbon atom can be taken together to form an oxo group; R3 represents hydrogen or C1-4 alkyl;

each R4 independently represents halogen, cyano, nitro, carboxy, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl, hydroxy, C<sub>1-4</sub> hydroxyalkyl, C<sub>1-4</sub> alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, amino, C1-4 alkylamino, C1-4 dialkylamino, formyl, C1-4 alkylcarbonyl, C1-4 alkoxycarbonyl or C1-4 haloalkoxycarbonyl, or two substituents R4 on the same carbon atom can be taken together to form an oxo group, and additionally one of the substituents R4 can represent a saturated, unsaturated or partially unsaturated 5- or 6-membered ring which can optionally contain from 1 to 3 heteroatoms selected from N, O and S and which can be optionally substituted with one or more substituents R5: each R5 independently represents halogen, hydroxy, nitro, cyano, amino, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy or C1-4 alkylcarbonyl, or two substituents R5 on the same carbon atom can be taken together to form an oxo group; and heteroarvl in the above definitions represents pyridine.

43. (Currently amended) A compound according to claim 42 wherein A represents imidazole, pyrazole, isoxazole, oxazole, thiazole, 2,5-dihydrofuran, thiophene, pyridine, 4#-pyran, eyelopentene, 2,3-dihydrooxazole or 4,5-dihydropyrazole which can be optionally substituted with one to four substituents R<sup>2</sup>.

pyrazine, pyrimidine or pyridazine;
or a salt and or solvate thereof.

- 44. (Currently amended) A compound according to claim 43 wherein A represents imidazole, pyrazole, isoxazole or oxazole which can be optionally substituted with one or two substituents  $\mathbb{R}^2$ .
- 45. (Previously presented) A compound according to claim 44 wherein A represents imidazole which can be optionally substituted with one substituent R2.
- 46. (Previously presented) A compound according to claim 42 wherein each  $R^2$  independently represents halogen,  $C_{1-4}$  alkyl or  $C_{1-4}$  haloalkyl, or two substituents  $R^2$  on the same carbon atom can be taken together to form an oxo group.
- 47. (Previously presented) A compound according to claim 42 wherein D represents phenyl optionally substituted with a fluoro atom.
- 48. (Previously presented) A compound according to claim 42 wherein L represents a single bond.
- 49. (Previously presented) A compound according to claim 42 wherein B represents phenyl optionally substituted with one to three groups R4 or B represents cyclohexyl.
- 50. (Previously presented) A compound according to claim 42 wherein each  $R^4$  independently represents halogen,  $C_{1-4}$  alkyl, C1-4 alkoxy or C1-4 haloalkyl.

51. (Previously presented) A compound according to claim 42 of formula Id:

Td

wherein:

B represents phenyl optionally substituted with one to three groups R4; and

each R4 independently represents halogen, C1-4 alkyl, C1-4 alkoxy or  $C_{1-4}$  haloalkyl.

- 52. (Previously presented) A compound according to claim 51 wherein B represents 3-fluoro-4-methoxyphenyl.
- 53. (Previously presented) A compound according to claim 42 wherein each R1 independently represents hydrogen, C1-6 alkyl or phenyl optionally substituted with one or more halogen, C1-4 alkyl or C1-4 alkoxy groups.
- 54. (Previously presented) A compound according to claim 42 wherein the compound is N-[4-[4-chloro-5-(3-fluoro-4-

methoxyphenyl)imidazol-1-yl]phenylsulfonyl]phosphoramidic acid, or a salt or solvate thereof.

- 55. (Previously presented) A compound according to claim 54 wherein the compound is N-[4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)] imidazol-1-yl]phenylsulfonyl]phosphoramidic acid.
- 56. (Previously presented) Process for preparing a compound of formula I according to claim 42 which comprises:
- (a) when in a compound of formula I each  $R^1$  is different from hydrogen, reacting a sulfonamide of formula II



ΙI

wherein A, L, B and D have the meaning described in claim 42, with a compound of formula III

$${\tt XP}$$
 (O) (OR<sup>1a</sup>)  $_2$ 

TTT

wherein X represents H or Cl and wherein each  $R^{1a}$  independently represents any of the meanings described for  $R^{1}$  in claim 42 except for hydrogen, in the presence of a base, or

alternatively, reacting a sulfonamide of formula II in which the group  $-SO_2NH_2$  is in anionic form with a compound of formula III; or

(b) when in a compound of formula I each  $\mathbb{R}^1$  represents hydrogen, hydrolyzing a compound of formula Ia'

Ia'

wherein A, L, B and D have the meaning described in claim 42 and wherein  $R^{1s'}$  represents any of the meanings described for  $R^1$  in claim 42 except for hydrogen and benzyl, or alternatively, hydrogenating a compound of formula Ia''

wherein A, L, B and D have the meaning described in claim 42; or (c) when in a compound of formula I one of the substituents  $R^1$  represents hydrogen and the other is different from hydrogen, monodealkylating a compound of formula Ia'''

Talli

wherein A, L, B, D and  $R^{1s}$  have the meaning described in claim 42 and wherein  $R^{1s'''}$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl or phenyl $C_{1-3}$  alkyl, where the phenyl group can be optionally substituted with one or more halogen,  $C_{1-4}$  alkyl or  $C_{1-4}$  alkoxy groups; or (d) transforming, in one or a plurality of steps, a compound of formula I into another compound of formula I.

57. (Previously presented) The process of claim 56, which further comprises reacting the compound of formula I with a base or an acid to give the corresponding addition salt.

- 58. (Previously presented) A pharmaceutical composition which comprises an effective amount of a compound of formula I according to claim 42 or a pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically acceptable excipients.
  - 59. 61. (Canceled)
- 62. (Currently amended) The method of claim 59 A method for the treatment of diseases mediated by cyclooxygenase-2 which comprises administering to a subject in need thereof an effective amount of a compound of formula I according to claim 42 or a pharmaceutically acceptable salt or solvate thereof, wherein the disease mediated by cyclooxygenase-2 is selected from the group consisting of: pain resulting from surgery or dental surgery; low back and neck pain; headache; toothache; pain associated with cancer; neuralgia; arthritis; degenerative joint diseases; gout; ankylosing spondylitis; tendinitis; pain or inflammation associated with sprains, strains or other traumatisms; synovitis; myosotis myositis; dysmenorrhea; inflammatory bowel disease; ocular inflammatory diseases; corneal-transplants; skin inflammatory diseases; systemic inflammatory processes; bursitis; lupus erythematosus; common cold; rheumatic fever; symptoms associated with influenza or other viral infections; preterm labour; asthma; bronchitis;

familial adenomatous polyposis; liver cancer; bladder cancer; pancreatic cancer; ovarian cancer; prostate cancer; cervical cancer; lung cancer; breast cancer; skin cancer; gastrointestinal cancers; eerebral infarction; epilepsy; type I diabetes; dementia; Parkinson's disease; amyotrophic lateral sclerosis; and atherosclerosis.